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P A I N
TRPV1 promotes opioid analgesia during inflammation
Lilian Basso1, Reem Aboushousha1, Churmy Yong Fan2, Mircea Iftinca1, Helvira Melo1, 
Robyn Flynn1, Francina Agosti3, Morley D. Hollenberg1, Roger Thompson2, Emmanuel Bourinet3, 
Tuan Trang2, Christophe Altier1*
Pain and inflammation are inherently linked responses to injury, infection, or chronic diseases. Given that acute 
inflammation in humans or mice enhances the analgesic properties of opioids, there is much interest in determining 
the inflammatory transducers that prime opioid receptor signaling in primary afferent nociceptors. Here, we found 
that activation of the transient receptor potential vanilloid type 1 (TRPV1) channel stimulated a mitogen-activated 
protein kinase (MAPK) signaling pathway that was accompanied by the shuttling of the scaffold protein -arrestin2 
to the nucleus. The nuclear translocation of -arrestin2 in turn prevented its recruitment to the -opioid receptor 
(MOR), the subsequent internalization of agonist-bound MOR, and the suppression of MOR activity that occurs 
upon receptor desensitization. Using the complete Freund’s adjuvant (CFA) inflammatory pain model to examine 
the role of TRPV1 in regulating endogenous opioid analgesia in mice, we found that naloxone methiodide (Nal-M), 
a peripherally restricted, nonselective, and competitive opioid receptor antagonist, slowed the recovery from 
CFA-induced hypersensitivity in wild-type, but not TRPV1-deficient, mice. Furthermore, we showed that inflammation 
prolonged morphine-induced antinociception in a mouse model of opioid receptor desensitization, a process that 
depended on TRPV1. Together, our data reveal a TRPV1-mediated signaling pathway that serves as an endogenous 
pain-resolution mechanism by promoting the nuclear translocation of -arrestin2 to minimize MOR desensitization. 
This previously uncharacterized mechanism may underlie the peripheral opioid control of inflammatory pain. 
Dysregulation of the TRPV1–-arrestin2 axis may thus contribute to the transition from acute to chronic pain.
INTRODUCTION
Pain modulation and inflammation are two integrated biological 
responses that function in cooperation after injury. Particularly 
known for their analgesic properties, opioids target receptors 
expressed throughout the afferent pain pathway, including central 
and peripheral nerve terminals of primary afferent neurons (1–3). 
Drugs and local endogenously produced opioids, -endorphin, 
enkephalins, and dynorphins, exert efficient inhibitory control of 
pain at both spinal (1, 2) and peripheral sites after inflammation 
(4–8). At inflammatory sites, immune-derived opioids are released 
to counteract pain effectively and facilitate healing. Moreover, an 
alteration in the endogenous opioid system in the spinal cord was 
proposed to prevent the transition from acute inflammatory to chronic 
pain (1), particularly through tonic -opioid receptor (MOR) activity 
that suppresses hyperalgesia after resolution of inflammation. Thus, 
both endogenous and xenobiotic opioids are most effective imme-
diately after tissue injury, suggesting that the early phases of inflam-
mation primes opioid receptor signaling in nociceptive afferent 
neurons (7, 9). Alterations in this priming might contribute to a de-
crease in the therapeutic window of opioids, requiring increased 
analgesic doses that can lead to side effects. Accordingly, at sites of 
acute local inflammation in humans or mice, the analgesic proper-
ties of opioids are enhanced (10), whereas application of opioids to 
a human peripheral nerve plexus does not elicit analgesia in non-
inflamed tissue (11). At these sites, the transient receptor potential 
vanilloid type 1 (TRPV1) channel is the main endpoint target of in-
flammatory mediators, including reactive oxygen species, metabolites 
of polyunsaturated fatty acids, and protons or toxins released by 
pathogens that directly activate (12) and sensitize the channel by G 
protein–coupled receptor (GPCR)–targeted mediators (bradykinin, 
prostaglandin E2, and proteases) (13–16). These inflammatory pro-
cesses, in turn, cause hyperalgesia during tissue inflammation (17) 
and in many immune-associated diseases (12, 18–21).
Along these lines, previous work reported functional interactions be-
tween the signaling pathways of TRPV1 and MORs, and findings suggest 
that MORs found in TRPV1+ primary afferent nociceptors are essential 
contributors to analgesic tolerance (22); however, the underlying molec-
ular mechanisms remain unknown. We set out to test whether TRPV1 
could prime opioid-induced antinociception by minimizing receptor 
desensitization and enhancing opioid receptor signaling. As a central 
regulator of MOR function and desensitization, the role of -arrestin2 
was investigated in relation to TRPV1 activation. We found that, upon 
treating TRPV1- expressing human embryonic kidney (HEK) cells with 
capsaicin, the active component of chili peppers that binds to the chan-
nel, -arrestin2 is trafficked to the nucleus through a calcium-dependent 
mitogen-activated protein kinase (MAPK) signaling pathway. As a result 
of this exclusion of -arrestin2 from the cytosol, activated MORs were 
unable to recruit -arrestin2 and become internalized during agonist- 
induced desensitization. Using the complete Freund’s adjuvant (CFA) 
inflammatory pain model, we then investigated the role of TRPV1 in 
both endogenous and exogenous opioid-induced antinociception.
Although TRPV1, MOR, and -arrestin2 are well-known players 
in inflammatory pain and analgesia, our data uncover an unappreciated 
mechanism whereby inflammation-mediated activation of TRPV1 
might minimize the desensitization of opioid receptors to enhance 
analgesia. This TRPV1 opioid receptor interaction could be phar-
macologically targeted in clinical settings to improve pain manage-
ment by opioids.
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RESULTS
TRPV1 activation induces both -arrestin2 nuclear 
localization and extracellular signal–regulated kinase  
1 and 2 phosphorylation
Previous work showed that -arrestin2 functionally interacts with 
TRPV1 (23), and other findings revealed that TRPV1 activation 
blocks opioid-dependent phosphorylation of MOR (24). We thus 
asked whether channel activation could, through competitive interaction, 
prevent the recruitment of -arrestin2 to the opioid receptor at the 
plasma membrane. Using spinning disk confocal microscopy on 
TRPV1-expressing HEK cells, we first examined the fate of the yellow 
fluorescent protein (YFP)–fused -arrestin2 (-arrestin2–YFP) after 
channel activation. Although we expected -arrestin2 to accumulate 
at the plasma membrane, stimulation of TRPV1 by resiniferatoxin 
(RTX) or capsaicin promoted a rapid translocation of -arrestin2 to 
the nucleus (Fig. 1, A and B). Image quantification indicated that 
>70 and ~50% of TRPV1-mCherry–expressing cells displayed nuclear 
translocation of -arrestin2 after 15 min of TRPV1 stimulation by 
RTX or capsaicin, respectively (Fig. 1C and fig. S1A). This translocation 
was slowly reversed upon washout of capsaicin, did not occur in the 
absence of the channel (fig. S1, A and B), and specifically targeted 
the nucleus, as confirmed by staining of nuclei with Hoechst blue in 
TRPV1-stimulated cells (fig. S1C). To get a more precise analysis of 
the time course of the effect, we assessed -arrestin2 translocation 
by bystander bioluminescence resonance energy transfer (BRET) 
assay (25) using -arrestin2 conjugated to Renilla luciferase (rLuc) 
coexpressed with the Renilla green fluorescent protein (rGFP) fused 
to the nuclear localization sequence (NLS) PKKKRKVEDPKS, which 
targets the nucleus (Fig. 1D). As was previously reported, this BRET 
approach enables the trafficking of proteins in the same subcellu-
lar compartments to be monitored and thus quantitatively assesses 
the nuclear translocation of -arrestin2 after channel stimulation in a 
concentration- and time-dependent manner. When TRPV1 was ex-
pressed, increasing the concentration of capsaicin at 37°C induced 
an increase in bystander BRET signal between  βARR2-rLuc and 
rGFP-NLS, which indicated the accumulation of -arrestin2 in the 
nucleus, in proximity to the rGFP-NLS (Fig. 1, E and F). This effect 
depended on the presence of TRPV1 (fig. S1D), occurred at concen-
trations of capsaicin >10 nM, with 2 min of channel activation, and 
reached a plateau at ~12 min after treatment (Fig. 1E). In contrast, 
TRPA1, another calcium-permeant member of the TRP channel 
family, failed to mediate -arrestin2 accumulation in the nucleus 
(fig. S1, E and F), thus highlighting a specific TRPV1-driven calcium 
signaling pathway that caused -arrestin2 translocation.
Arrestins are important scaffolds for the MAPK/extracellular 
signal–regulated kinase 1 (ERK1) and ERK2 (hereafter, ERK1/2) 
signaling pathway, which is also sensitive to the intracellular Ca2+ 
concentration. We thus tested the effect of TRPV1 stimulation on 
the activation of ERK1/2. In TRPV1-expressing HEK 293 cells, RTX 
induced a transient phosphorylation (and thus activation) of ERK1/2 
at 5 min after stimulation (Fig. 1, G and H). ERK1/2 activation was 
blocked by chelating extracellular Ca2+ with 10 mM EGTA (Fig. 1I), 
which also prevented -arrestin2 nuclear translocation (Fig. 1J), 
suggesting that Ca2+ influx through activated TRPV1 mediates both 
processes. Although different isoforms of protein kinase C (PKC) 
are implicated upstream of ERK1/2 activation (26, 27), we found that 
pharmacological inhibition of PKC–beta II (PKCII) by CGP53353 
blocked ERK1/2 phosphorylation in response to TRPV1 stimulation, 
whereas selective inhibition of the  or I isoforms with GF109203X 
did not (fig. S1, G and H). Accordingly, TRPV1 activation by RTX 
seemed to directly activate PKCII (fig. S1I). Together, these findings 
suggest that the activation of TRPV1 engages a signaling cascade 
involving both the Ca2+- and PKCII-dependent activation of ERK1/2, 
which coincides with the translocation of -arrestin2 to the nucleus.
TRPV1 activation disrupts the MOR–-arrestin2 interaction 
and receptor internalization
To determine whether TRPV1-induced translocation of -arrestin2 
would prevent its recruitment to the activated MOR, we monitored 
the interaction of the Renilla luciferase–fused MOR (MOR-Rluc8) 
with the Venus fluorescent protein–fused -arrestin2 (-arrestin2–
Venus) using BRET1 assay in HEK 293 cells. Activation of MOR 
with its specific synthetic opioid peptide DAMGO ([D-Ala2, N-MePhe4, 
Gly-ol]-enkephalin) induced the recruitment of -arrestin2 to MOR 
(Fig. 2), as indicated by an increase in BRET signal that plateaus 
after 400 s of treatment. In the absence of TRPV1, application of 
500 nM capsaicin did not induce a BRET response or affect the 
DAMGO-induced recruitment of -arrestin2 to MOR. However, in 
TRPV1-expressing cells, whereas capsaicin alone had no effect, 
cotreatment with 10 M DAMGO completely blocked the interaction 
between MOR and -arrestin2 (Fig. 2, B and C). This effect was 
observed at low and even saturating concentrations of DAMGO 
(Fig. 2D). Furthermore, use of the reversed pair of BRET biosensors 
(ARR2-Rluc + MOR-YFP) yielded similar results (fig. S2), thus 
confirming the inhibitory effect of TRPV1 activation on MOR– 
-arrestin2 interaction. Moreover, coimmunoprecipitation of MOR 
with TRPV1 indicated the formation of a receptor-channel signaling 
complex at steady state, which was unaffected by DAMGO treatment 
(Fig. 2E), and saturating BRET signals obtained for coexpression of 
channel and receptor suggested a close interaction between MOR 
and TRPV1, with or without DAMGO (Fig. 2F). Therefore, our data 
show that proximity of TRPV1 to MOR alters the -arrestin2–biased 
agonism of DAMGO by redirecting -arrestin2 or preventing its 
recruitment to the receptor upon channel activation. We also found 
that this mechanism applies to other neuronal GPCRs, because the 
proteinase-activated receptor-2 (PAR2), which like MOR is involved 
in inflammatory pain, showed impaired -arrestin2 recruitment after 
cotreatment with capsaicin (fig. S2, D and E).
Given that -arrestin2 is an essential modulator of MOR desen-
sitization and recycling, we next tested the functional outcome of 
TRPV1 activation on receptor internalization. Using confocal 
microscopy, we found that, as previously reported, exposure to 1 M 
DAMGO for 20 min promoted robust receptor internalization in 
HEK 293 cells expressing MOR-YFP and TRPV1-mCherry. In con-
trast, cells costimulated with DAMGO and capsaicin (or DAMGO + 
RTX; fig. S3A) had less internalized receptors (Fig. 3, A and B). 
Imaging of cells expressing -arrestin2–YFP, TRPV1–cyan fluo-
rescent protein (CFP), and MOR-mCherry revealed that, upon 
DAMGO treatment, -arrestin2 colocalized with internalized MOR- 
containing vesicles (fig. S3A, middle panels). After combined appli-
cation of DAMGO with RTX however, -arrestin2 sequestered in 
the nucleus, because of channel stimulation, thus preventing the 
agonist- induced internalization of MOR (Fig. 3, A and B, and 
fig. S3A, bottom panels). Deletion of -arrestin2 using a CRISPR 
-arrestin2 knockout cell line (fig. S3B) eliminated DAMGO-evoked 
internalization and thus mimicked the DAMGO with capsaicin 
condition in -arrestin2 wild-type (WT) cells (fig. S3C). Next, using 
a quantitative bystander BRET assay developed by Namkung et al. 
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Fig. 1. Activation of TRPV1 mediates translocation of -arrestin2 to the nucleus. (A to C) Spinning disk confocal imaging (A and B) and quantification (C) of -arrestin2 
nuclear translocation in HEK cells transfected with plasmids expressing TRPV1-mCherry (red; B) and -arrestin2–YFP (green) and treated with either bath-applied 10 nM 
RTX at 37°C for the indicated times (A) or 1 M capsaicin for 15 min (B). Arrows (A) indicate the nuclear localization of -arrestin2–YFP. Scale bars, 10 m. Data (C) are means ± 
SEM of at least 100 cells per condition from five experiments. **P < 0.001 and ***P < 0.0001 compared to time zero by an unpaired t test. (D) Illustration of the bystander 
BRET assay used to monitor the trafficking of -arrestin2 to the nucleus. PM, plasma membrane; NM, nuclear membrane. (E and F) Time course of net bystander (E) and 
maximum (F) BRET measured in HEK cells expressing TRPV1, 2ARR-rLucII, and Renilla GFP-NLS and exposed to various concentrations of capsaicin (caps.) injected at time 
zero. Inset: Image of nuclear localization of the GFP-NLS signal in cells costained with 4′,6-diamidino-2-phenylindole (DAPI). In (F), data were normalized to control (ctrl; vehicle) 
conditions and are means ± SEM of three experiments. *P < 0.05 and **P < 0.001 by one-way analysis of variance (ANOVA) and Bonferroni post hoc test. (G and H) Western 
blotting and analysis of phosphorylated and total ERK in HEK cells transfected with plasmid expressing TRPV1 and treated with 10 nM RTX for the indicated times. Blots 
are representative of three experiments; data are means ± SEM of three experiments. (I and J) Effect of the Ca2+-chelator EGTA (10 mM) on RTX-induced pERK1/2 at 5 min 
as assessed by Western blotting (I) and on RTX-induced -arrestin2 nuclear translocation at 15 min as assessed by confocal microscopy (J). Scale bar, 20 m. Blots and 
image are representative of three experiments; data are means ± SEM of three experiments. *P < 0.05; **P < 0.01 by unpaired t test.
 o
n
 April 2, 2019
http://stke.sciencem
ag.org/
D
ow
nloaded from
 
Basso et al., Sci. Signal. 12, eaav0711 (2019)     2 April 2019
S C I E N C E  S I G N A L I N G  |  R E S E A R C H  A R T I C L E
4 of 14
(25), we took advantage of the rGFP-tagged FYVE domain of endofin 
(Q739-K806) to monitor receptor internalization into early endo-
somes (Fig. 3C) upon treating HEK 293 cells with DAMGO or 
DAMGO and capsaicin. Activation of MOR by 1 M DAMGO at 
37°C induced an increase in bystander BRET signal between MOR-
Luc8 and rGFP-FYVE selectively targeted to intracellular vesicles. 
The degree of receptor internalization peaked at ~15 min after 
DAMGO application and then plateaus. In contrast, as observed 
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Fig. 2. Activation of TRPV1 prevents the DAMGO-induced interaction between MOR and -arrestin2. (A and B) BRET measured over time in HEK cells expressing 
MOR-Rluc8 and -arrestin2–Venus (ARR2-Venus) and exposed to 10 M DAMGO (blue), 500 nM capsaicin (red), or both (green) injected a time zero, either in the absence 
(A) or presence (B) of TRPV1 expression. Data are means ± SEM of three experiments. (C) Quantification of the BRET signal, obtained from the experiments represented in 
(A) and (B). Data are means ± SEM of the last four points on the time-course curve, from three experiments. ***P < 0.001. (D) Dose-response curve of the net BRET between 
MOR-Rluc8 and -arrestin2–Venus in the cells described in (B) exposed to increasing concentration of DAMGO (blue) or DAMGO and capsaicin (green). (E) Co-immuno-
precipitation (IP) from HEK cells expressing MOR-YFP alone or with TRPV1-hemagglutinin (HA) and exposed to vehicle (lanes 1 to 3) or 1 M DAMGO (lane 4). Blot is rep-
resentative of three experiments. WB, Western blot. (F) Net BRET saturation curves between MOR-Rluc8 and TRPV1-YFP or TRPA1-YFP in HEK cells. Data are representative 
of three independent experiments.
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with confocal imaging, capsaicin cotreatment was able to blunt the 
internalization of MOR in early endosomes (Fig. 3, D and E).
TRPV1 activation prevents MOR desensitization
To assess the functional consequence of -arrestin2 nuclear translo-
cation on MOR function and desensitization, we measured the 
inhibition of N-type voltage-gated calcium channel (VGCC), as a 
surrogate of MOR-induced Gi/o protein activation. In WT HEK 293 
cells expressing TRPV1 with MOR and the Cav2.2 subunit, activation 
of MOR by 1 M DAMGO induced a rapid and robust inhibition of 
Cav2.2 current (Fig. 4). This inhibition was not observed in the 
absence of MOR or in response to TRPV1 activation by capsaicin 
(fig. S4A), confirming that Cav2.2 responded specifically to 
DAMGO-bound MOR but not to TRPV1 activation. Desensitization 
of MOR by DAMGO preincubation for an hour prevented the acute 
DAMGO-induced modulation of Cav2.2 currents (Fig. 4, A and B). 
This effect was relieved by prolonged washout of DAMGO to allow 
recycling of internalized MOR (fig. S4B). Furthermore, preincubation 
with a combination of DAMGO and capsaicin could restore the 
acute MOR-promoted Cav2.2 inhibition (Fig. 4, A and B), an effect 
lost in the absence of TRPV1 (fig. S4C). In contrast, MOR activation 
resulted in a robust Cav2.2 inhibition in -arrestin2 knockout 
(ARRB2−/−) HEK 293 cells, despite pretreatment with DAMGO or 
DAMGO and capsaicin, supporting our hypothesis that -arrestin2 
translocation is essential in driving the TRPV1-induced blockade of 
MOR desensitization. Reintroducing -arrestin2 to ARRB2−/− HEK 
cells reestablished receptor desensitization and its relief triggered by 
TRPV1 activation (Fig. 4, A and B).
TRPV1-induced translocation of -arrestin2 occurs in dorsal 
root ganglion nociceptors
To examine -arrestin2 translocation in TRPV1-expressing neurons, 
we immunostained acutely dissociated dorsal root ganglion (DRG) 
neurons from YFP-fused channel rhodopsin-2 that was expressed 
in TRPV1-lineage neurons (TRPV1-ChR2-EYFP). Whereas the 
subcellular distribution of -arrestin2 was cytosolic in naïve DRG 
neurons of all sizes, capsaicin rapidly translocated -arrestin2 into 
the nucleus, an effect that was only observed in YFP+ neurons 
(Fig. 5, A and B). When looking at the functional effect of MOR 
activity in DRG neurons, we found that both WT and TRPV1−/− 
neurons exhibited inhibition of N-type calcium current in response 
to acute 1 M DAMGO (Fig. 5, C and D). However, desensitization 
of the receptor by prolonged exposure (1 hour) to DAMGO 
canceled out the acute inhibitory effect of DAMGO on N-type 
channels in both WT and TRPV1−/− neurons (Fig. 5D). As found in 
heterologous expression systems, preincubation with a combination 
of DAMGO and capsaicin (100 nM) restored N-type inhibition 
induced by acute MOR activation (Fig. 5D). This effect occurred in 
TRPV1+, capsaicin-responsive DRG neurons from WT animals. 
However, capsaicin cotreatment could not restore MOR-induced 
N-type inhibition in TRPV1−/− neurons (Fig. 5D). Overall, these 
data suggest that activation of TRPV1 minimizes desensitization of 
MOR in a -arrestin2–dependent fashion.
TRPV1 stimulates endogenous opioid-mediated analgesia 
during inflammation
Given that TRPV1 is a central integrator of inflammatory signals 
(28–30), we tested whether the TRPV1-MOR interaction that we 
described in vitro regulated opioid analgesia in vivo. TRPV1 is likely 
the best-characterized sensory transducer expressed in polymodal 
C fibers, which process both thermal and mechanical hyperalgesia 
during long-lasting inflammation (31). Using the CFA model of 
chronic inflammatory pain, we evaluated peripheral immune-derived 
endogenous opioid antinociception (6, 32–35) in WT and TRPV1−/− 
mice by measuring paw withdrawal threshold (PWT) during the 
acute and later (resolution) phase of inflammation. In WT animals, 
PWT was decreased by 50% at day 4 after intraplantar injection of 
CFA, and animals started to recover at day 6. Treatment with 
naloxone methiodide (Nal-M), a peripherally restricted nonselective 
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Fig. 3. Activation of TRPV1 prevents MOR internalization. (A and B) Confocal 
microscopy of HEK cells expressing MOR-YFP (green) and TRPV1-mCherry (red) 
exposed to vehicle, 10 M DAMGO, or 10 M DAMGO and 1 M capsaicin for 
30 min. Scale bar, 10 m. Number of MOR+ vesicles per cell (white arrows) were 
counted with ImageJ software. Data are means ± SEM of at least 100 cells per 
condition from three independent experiments. *P < 0.05 and ***P < 0.001 by 
Kruskal-Wallis test followed by Dunn’s post hoc test. ns, not significant. (C) Illustration 
of the bystander BRET-based approach for monitoring MOR trafficking to FYVE-tethered 
early endosomes (EE) in response to DAMGO or DAMGO and capsaicin. Upon treatment 
with DAMGO, the internalized MOR-rLuc8 induces an increase in BRET signal 
compared to unstimulated condition (left). On the basis our observations in (A), 
cotreatment with DAMGO and capsaicin (right) will reduce the BRET response by 
preventing receptor trafficking to FYVE-tethered early endosomes. (D) Bystander 
net BRET over time in HEK cells exposed to vehicle [phosphate-buffered saline 
(PBS)] or 10 M DAMGO at 37°C for 20 min. Data were normalized to their respective 
baseline and are the means ± SEM from three experiments. (E) Bar graph repre-
senting the area under the curve (AUC) of the net bBRET data presented in (D). 
***P < 0.01 by unpaired t test.
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Fig. 4. Activation of TRPV1 prevents acute desensitization of DAMGO-mediated 
inhibition of the Cav2.2 current. (A) Representative Ca2+ current traces (evoked 
at +10 mV from a holding potential of −80 mV during 30 ms) in HEK cells expressing 
Cav2.2 (+21 and 2a), MOR1, and TRPV1 and acutely treated with vehicle (black 
symbol) or 1 M DAMGO (blue symbol). The current was recorded in control conditions 
(left traces), after 1 hour of preincubation with 1 M DAMGO (middle traces, acute 
desensitization), and 1 hour after preincubation with 1 M DAMGO and 100 nM 
capsaicin (right traces). Experiments were repeated using -arrestin2 knockout 
(ARRB2−/−) HEK cells with or without transfection with -arrestin2 expression 
plasmid. Traces are representative of three independent experiments. (B) Percentage 
of peak current inhibition induced by 1 M DAMGO in untreated (white), 
DAMGO-pretreated (blue), or DAMGO and capsaicin–pretreated cells (green) at 
37°C. Data are means ± SEM from three independent experiments, from (left to 
right) 15, 9, 9, 10, 9, 10, 9, 10, and 10 HEK cells. *P < 0.01 by one-way ANOVA and 
Bonferroni post hoc test.
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Fig. 5. Activation of TRPV1 promotes -arrestin2 nuclear translocation, which 
results in reduced MOR desensitization in DRG neurons. (A) Representative 
confocal microscopy images of -arrestin2 immunostaining (red) in TRPV1-expressing 
DRG neurons (green) isolated from Ai32/TRPV1-cre mice. Neurons were untreated 
(control) or stimulated with 100 nM capsaicin for 10 min. Images are representative 
of five independent experiments. (B) Linescan corresponding to the image in (A) 
and representing -arrestin2 cellular distribution. a.u., arbitrary units. (C) Representative 
N-type current traces (recorded in the presence of 10 M nifedipine) from a 
capsaicin-sensitive DRG neuron upon application of vehicle (black symbol) or 1 M 
DAMGO (blue symbol). Recordings were done in DRG neurons from WT and 
TRPV1−/− mice for different conditions of pretreatment (vehicle, DAMGO, and 
DAMGO and capsaicin at 37°C) as also described in Fig. 4A. Inset: TRPV1 current 
elicited by 100 nM capsaicin at a holding potential of −80 mV. Data are representative 
of three independent experiments. (D) Percentage of peak current inhibition 
recorded in the experiment represented in (C), treated as indicated. Data are 
means ± SEM from three independent experiments, from (left to right) 8, 7, 8, 
8, 6, and 15 DRG neurons. *P < 0.01 by one-way ANOVA and Bonferroni post 
hoc test.
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and competitive opioid receptor antagonist, delayed the recovery 
time as attested by the increased PWT from day 6 to day 10 in both 
male (Fig. 6, A and B) and female mice (fig. S5, A and B). In 
TRPV1−/− mice, we found that PWT was decreased by 40% at day 4 
and then recovered gradually until day 14. Treatment with Nal-M 
in both TRPV1−/− male (Fig. 6, A and B) and female mice (fig. S5, A 
and B) had no effect on PWT at any time of the treatment. This 
absence of endogenous opioid analgesia in TRPV1−/− mice was due 
neither to a difference in inflammation (edema was similar between 
WT and knockout mice) nor to the capacity of pain-modulating 
immune cells to produce endogenous opioids and infiltrate the 
inflamed paw at day 8 of CFA (fig. S6, A to C). Thus, as previously 
reported, local opioid receptor signaling is fine-tuned by inflammation 
(34), and our results indicate that TRPV1 is a central contributor to 
this process.
TRPV1 prevents peripheral desensitization of  
opioid-induced analgesia
To determine whether TRPV1 contributes to the increased efficacy 
of exogenous opioids in inflammatory conditions (36), we used an 
in vivo paradigm of acute opioid receptor desensitization induced 
by repetitive injection of morphine (10 mg/kg intraperitoneally, 
twice daily for 3 days; Fig. 7A). We then assessed the dose response of 
morphine analgesia in CFA-inflamed mice, treated or not with mor-
phine for 3 days. To distinguish central versus peripheral effects, we 
determined morphine potency [median effective dose (ED50)] in 
mice that were given escalating doses of morphine via intrathecal 
(central) or local (peripheral) injection into the inflamed paw (Fig. 7, 
B and C). When administered intrathecally in morphine-naïve 
mice, morphine dose-dependently attenuated CFA-induced me-
chanical hypersensitivity: The ED50 was comparable in WT and 
TRPV1−/− mice, suggesting that TRPV1 did not alter morphine anti-
nociceptive potency in mice without previous exposure to morphine 
(Fig. 7C). In other words, acute morphine antinociception was not 
affected by the absence of TRPV1. By contrast, after repeated mor-
phine treatment, there was a notable reduction in morphine anti-
nociceptive potency (meaning, increased ED50) (Fig. 7B), suggesting 
a decreased capacity of MOR to respond to morphine. When admin-
istered locally in the inflamed paw of saline-treated CFA-inflamed 
mice, morphine dose-dependently reduced mechanical hypersensi-
tivity (Fig. 7D), thus confirming previous work that peripheral 
opioid receptors mitigate inflammatory pain under basal conditions 
(6, 37, 38). However, as opposed to what is observed centrally, pe-
ripheral morphine potency was maintained in chronic morphine- 
treated WT mice (Fig. 7, D and E). This result indicated that local 
inflammation prevents peripheral MOR desensitization upon chronic 
morphine treatment. This effect is dependent on the presence of 
TRPV1, as TRPV1−/− mice exhibit a decrease in peripheral morphine 
potency (increased ED50) as observed for centrally administered 
morphine (Fig. 7, D and E). Thus, our findings show that TRPV1 is 
responsible for maintaining peripheral opioid receptor signaling in 
nociceptors in the setting of inflammation. Overall, our results sug-
gest a model wherein activation of TRPV1 during an inflammatory 
insult translocates -arrestin2 to the nucleus, which in turn pre-
vents opioid-induced recruitment of -arrestin2 to MOR and ensues 
receptor desensitization, thus increasing opioid potency at peripheral 
nociceptors.
DISCUSSION
Previous studies proposed a positive modulation of opioid analgesia 
in inflammation (9, 39), whereas maladaptive processes occurring 
during resolution, combined with genetic and emotional predispo-
sition, precipitate the transition to opioid-insensitive chronic pain. 
Our findings shed light on the functional interplay between inflam-
mation and opioid analgesia, together with the mechanisms that 
lead to acute and/or persistent receptor desensitization.
The main finding of our work is that activation of the TRPV1 
acutely results in the trafficking of -arrestin2 from the cytosol to 
the nucleus. This channel-induced translocation attenuates the 
ability of -arrestin2 to mediate MOR desensitization, thereby 
maintaining the sensitivity of MOR-expressing nociceptors to the 
action of endogenously produced or exogenously administered 
opioids (Fig. 8). Furthermore, this mechanism of receptor regula-
tion might be shared among other nociceptor-expressed GPCRs, 
such as PAR2, that are localized in TRPV1-enriched membrane 
microdomains.
Of relevance to our observations, a number of studies have high-
lighted TRPV1 as a key effector of MOR, which is supported by the 
fact that both are expressed in small, unmyelinated DRG neurons 
(40). A substantial proportion of morphine analgesia is mediated by 
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Fig. 6. Peripheral endogenous opioidergic control of inflammatory pain is 
absent in TRPV1-deficient mice. (A) Mechanical sensitivity in mice assessed by 
PWTs using a dynamic plantar aesthesiometer. CFA was injected into the plantar 
surface of the right hind paw of WT (left graph) or TRPV1−/− (right) male mice. Mice 
received daily injections of 10 l of either PBS (blue circles; 10 mice per group) or 
Nal-M (Nal-Meth; 2 mg/ml; red squares) (10 WT and 8 TRPV1−/− mice per group) in 
the ipsilateral ankle from days 4 to 14, 30 min before assessment of mechanical 
threshold. Data are means ± SEM of PWT measured in the inflamed (CFA) ipsilateral 
paw (color) and saline-injected contralateral paw (gray) normalized to baseline. 
*P < 0.05, **P < 0.01, and ***P < 0.001 by two-way ANOVA and Bonferroni post hoc 
test. (B) Area under the PWT curves in (A) between days 6 and 10 were calculated 
and presented as the percentage of PWT normalized to vehicle-treated animals for 
each genotype. Data are means, min-max. ***P < 0.001 (or not significant) by 
Mann-Whitney U test.
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MORs on primary sensory neurons and their central terminals in 
the spinal cord where TRPV1 is also found. Thus, on one hand, 
acute morphine administration decreases the capsaicin-induced 
TRPV1 current (41) and reduces the insertion of functional TRPV1 
channels into the plasma membrane (42), whereas on the other 
hand, sustained morphine treatment may cause tolerance through 
the regulation of TRPV1 abundance (43). Here, our work reveals a 
reciprocal regulation of MOR by TRPV1 and identifies the molecular 
underpinnings of this process involving the TRPV1-triggered 
translocation of -arrestin2 to the nucleus. We found that TRPV1−/− 
mice were insensitive to endogenous opioid analgesia during the 
resolution of inflammation. We then showed that TRPV1 signaling 
overrode desensitization and maintained peripheral opioid receptor 
function when using an in vitro or in vivo opioid receptor desensi-
tization paradigm.
TRPV1 agonists, including a capsaicin-containing cream, are 
extensively used as local analgesics. Although Ca2+-dependent 
TRPV1 desensitization, inhibition of ion channels, and nerve de-
generation have been suggested to contribute to the analgesic effects 
of capsaicin, these mechanisms remain poorly defined, are revers-
ible, and thus do not explain the long-lasting, pain-relieving effects 
of capsaicin that persist for weeks after treatment (44–46). Previous 
work from Chen and Pan (47) determined that RTX-induced ablation 
of TRPV1-expressing afferent neurons prolonged opioid analgesia 
despite being accompanied by a reduction in MOR abundance. Never-
theless, our findings suggest that even while maintaining neuronal in-
tegrity, TRPV1 activity regulates -arrestin2 mobilization to fine-tune 
opioid receptor function when it is most needed. Additional work 
has described the direct inhibition of VGCCs by capsaicin in DRG 
neurons (48–50), which could contribute to decreasing excitatory neuro-
transmission in the afferent pain pathway. We did not observe such 
an effect in our hands when preincubating HEK cells or DRG neu-
rons with both DAMGO and capsaicin before washout and record-
ing N-type current inhibition. Furthermore, our BRET analysis suggests 
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a shift in MOR signaling that was likely caused by the absence of an 
interaction with -arrestin2 upon channel activation. Our electro-
physiology data indeed indicate that Gɣ (the  heterodimer of G 
proteins)–mediated modulation of N-type current was restored by 
TRPV1 activation; however, a direct assessment of Gi/o coupling to 
MOR will ascertain whether G protein–biased signaling is favored upon 
TRPV1 stimulation.
The main target of opioids used in the treatment of acute and 
chronic pain is represented by MOR, and their effect is mediated 
partly by inhibition of high voltage–gated N-type channels (51). 
Sustained agonist activation of MOR, however, produces cellular 
opioid tolerance, which is caused by the -arrestin2–dependent 
internalization of MORs that are trafficked to endosomal compartments 
(52). It is well established that receptor desensitization and inter-
nalization are two processes that participate, among other mecha-
nisms (including resensitization, down-regulation, or de novo 
receptor synthesis), in opioid tolerance (53–55). Therefore, further 
work will test this TRPV1-MOR paradigm in mouse models of opioid 
tolerance.
Last, our findings that -arrestin2 translocates to the nucleus 
after channel activation will stimulate some new lines of research 
on the genetic and epigenetic mechanisms of pain modulation by 
this TRPV1–-arrestin2 pathway. In contrast to previous studies 
showing a physical association between -arrestin2 and TRPV1 
(23), we could not find evidence of a direct interaction between the 
two proteins using a BRET assay, and observation by confocal 
microscopy denoted distinct subcellular localization of the two pro-
teins. -Arrestin2 was already reported to shuttle from the nucleus 
to the cytoplasmic compartment (56); however, the presence of a 
nuclear export signal in the 390 to 400 residues of the C-terminal 
domain excludes -arrestin2 from the nucleus. Mutations of this 
motif or pharmacological inhibition of nuclear export promote the 
translocation of -arrestin2 into the nucleus (56, 57). Several poten-
tial roles of -arrestin in the nucleus have been proposed, includ-
ing transcriptional regulation, DNA repair, and histone acetylation 
(58, 59). The rapid and reversible trafficking of -arrestin2 to the 
nucleus is not consistent with apoptotic pathways being engaged by 
the channel. However, we believe that transcriptional regulation 
mediated by TRPV1–- arrestin2 signaling could contribute to the 
analgesic effect of topical capsaicin formulations used for pain man-
agement. Future proteomic and transcriptional studies may ad-
vance our knowledge of the factors interacting with -arrestin2, 
as well as the genes regulated by TRPV1 signaling. It is likely that 
-arrestin2 has an important function in the plasticity of nociceptive 
circuits after inflammation.
Our data support the findings that TRPV1 activation blocks the 
opioid-dependent phosphorylation of the MOR by GPCR kinase 5 
(GRK5) (24). Thus, not only would TRPV1 activation attenuate the 
GRK-mediated recruitment of -arrestin2 to trigger MOR desensi-
tization and internalization but also the TRPV1- mediated translo-
cation of -arrestin2 from the cytosol would also diminish its effect 
on MOR and likely on other GPCRs present in nociceptors. Together, 
our work, along with the data of Scherer et al. (24), support the con-
cept that TRPV1 can bias MOR signaling through a dual mechanism 
involving the inhibition of receptor phosphorylation and the shuttling 
of -arrestin2 to the nucleus.
Although preventing Ca2+ influx through TRPV1 blocked - 
arrestin2 translocation, increasing the concentration of intracellu-
lar Ca2+ by activating the Ca2+-permeant channel TRPA1 did not 
stimulate the nuclear trafficking of -arrestin2. Therefore, the dy-
namics of these events will have to be investigated further to un-
derstand the spatial and temporal requirements for Ca2+ signaling 
to trigger - arrestin2 translocation and to determine whether there is 
cotrafficking of other signaling constituents (for example, GRK5) 
with -arrestin2. Inflammation affects the blood-nerve or blood-brain 
barrier and thereby influences the analgesic action of immune-derived 
opioids (60, 61). With that in mind, we compared the inflammatory 
response in TRPV1−/− and WT mice. The absence of difference 
in paw edema, T lymphocyte infiltration, and opioid production 
(fig. S6) suggested similar inflammatory processes between WT and 
TRPV1−/− mice in response to CFA injection and thus implied 
that nerve access is unlikely altered in TRPV1−/− mice.
Our results suggest a paradigm shift in our understanding of the 
regulation of opioid receptor function in response to inflammation 
and the maladaptive processes that could lead to pathological pain 
during tissue healing. Whereas clinical observations suggest that 
opioids are effective analgesics after acute injury, prolonged treat-
ment for chronic pain conditions is often accompanied by side 
effects that may relate to MOR desensitization and the subsequent 
requirement of higher opioid doses to achieve the same analgesic 
effect. Our data suggest that dysregulation of the TRPV1–-arrestin2 
signaling pathway could contribute to the transition from acute 
to chronic pain and highlight TRPV1 channels as potential modula-
tors of opioid analgesia. If used in conjunction with opioids, 
then TRPV1 agonists might improve the management of chronic 
and severe morphine-resistant pain by highjacking endogenous 
mechanisms of receptor desensitization (62), potentiating opioid 
analgesia and thus limiting dose escalation.
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Fig. 8. Model of the TRPV1-MOR interplay during opioid desensitization. 
Activation of MOR by exogenous or endogenous opioids mediates antinociception 
through the inhibition of N-type VGCCs in DRG neurons. Receptor desensitization 
and internalization is mediated by cellular signaling cascades, including the 
GRK-mediated phosphorylation of MOR, which in turn elicits -arrestin2–dependent 
internalization of the receptor into early endosomes. Our data suggest that stimulation 
of TRPV1 with capsaicin or inflammatory mediators (protons, lipids, and temperature) 
promotes the translocation of -arrestin2 to the nucleus and thus prevents MOR 
desensitization and internalization, facilitating inhibition of N-type channels.
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MATERIAL AND METHODS
Chemicals and drugs
The TRPV1 agonists RTX and capsaicin were obtained from Sigma- 
Aldrich. The MAPK inhibitor (U-0126) is from Cell Signaling 
Technology. The PKC inhibitor CGP53353 and GF109203X were 
purchased from Tocris Bioscience. Ionomycin was obtained from 
Alomone Labs.
Mice
Two-month-old C57bl/6 mice were obtained from Jackson Labora-
tories (Bar Harbor, ME). All mice were housed with a 12-hour 
light/12-hour dark cycle and under standard conditions with drinking 
water and food available ad libitum. All experiments were conducted 
on age-matched animals, under protocols approved by the University 
of Calgary Animal Care Committee and in accordance with the 
international guidelines for the ethical use of animals in research 
and guidelines of the Canadian Council on Animal Care. TRPV1−/− 
mice (strain B6.129X1-Trpv1tm1Jul/J) were originally obtained from 
the Jackson Laboratories and bred at the University of Calgary Animal 
Resource Center. Mice were genotyped with the following primers: 
WT, cctgctcaacatgctcattg [984 base pairs (bp)]; heterozygotes, 
tcctcatgcacttcaggaaa (450 and 984 bp); and TRPV1−/−, tggatgtggaat-
gtgtgcgag (450 bp; Jackson Laboratories). Transgenic Ai32/TRPV1-cre 
mice were bred in the University of Calgary Animal Resource Center 
(G. W. Zamponi) by crossing mice homozygous for the Rosa-CAG-
LSL-ChR2 (H134R)-EYFP-WPRE conditional allele (loxP-flanked 
STOP cassette) [strain B6;129S-Gt(ROSA)26Sortm32(CAG − 
 COP4*H134R/EYFP)Hze/J; hereafter Ai32] with mice expressing Cre 
recombinase in TRPV1 cells [strain B6.129-Trpv1tm1(cre)Bbm/J; 
hereafter TRPV1-cre] (both from the Jackson Laboratories).
CFA-induced inflammatory pain
Mice received 20 l of CFA (1 mg/ml; Sigma, St. Louis, MO) in the 
right hind paw, as previously described (61). They were acclimated 
to the dynamic plantar aesthesiometer testing chamber for 1 hour, 
two consecutive days before behavioral testing. From days 4 to 14 
after CFA injection, mice received either 10 l of PBS or Nal-M (2 
mg/ml) in the ipsilateral ankle. Mechanical threshold was assessed 
30 min after injection. Paw edema was measured throughout the 
experiment with a plethysmometer (Hugo Basile).
In vivo opioid receptor desensitization paradigm
Mice were injected with CFA or 20 l of saline as control in the 
morning. Morphine (10 mg/kg; Professional Compounding Centers 
of America Corp., London, Ontario, Canada) or 0.9% saline (Sigma) 
was injected intraperitoneally 1 hour after CFA and then again 
in the afternoon. Morphine injections were repeated twice daily, 
for two more consecutive days (day 1 and day 2). On day 3, me-
chanical nociceptive threshold was determined by the simplified 
up-and-down method using von Frey filament (63) in response to 
increasing doses of Morphine injected either intrathecally (at doses 
of 0, 1, 2.5, 5, 10, and 15 g) or locally (in the ankle, at doses of 
0, 2.5, 5, 10, 25, 30, and 40 g) in the inflamed paw.
Plasmids
TRPV1-YFP and TRPV1-Rluc have been previously described (14), 
TRPA1-YFP was constructed by cloning the TRPA1 coding sequence 
(a gift from A. Patapoutian) into pEYFP-N1. TRPV1-mCherry 
and TRPA1-mCherry were produced by cloning the mCherry 
sequence in place of YFP in TRPV1-pEYFP and TRPA1-pEYFP using 
(Not I and Kpn I). TRPV1-CFP was generated by replacing the YFP 
coding sequence of TRPV1-YFP with CFP from pECFP (Clontech). 
-Arrestin2–YFP and 2ARR-rLucII have been previously described 
(64). Rat MOR1-YFP, Cav2.2, Cav2a, and 2-1 subunits were gifts 
from G. W. Zamponi. The MOR-YFP plasmid was used to generate 
MOR1-HA by cloning sticky-ended oligos containing the HA tag 
(YPYDVPDYA) in place of YFP. MOR-Rluc8 was produced by 
using polymerase chain reaction (PCR) to introduce Age I and Not 
I sites to RLuc8 (a gift from M. Bruchas) to clone in place of YFP. 
-Arrestin2–Venus was generated as previously described (65). 
PKC- II–GFP was provided by S. S. G. Ferguson. -Arrestin2 
lentiCRISPR- V2 plasmids were a gift from M. Hollenberg and 
contained guide sequences identified in a genome-wide screening 
(65). Humanized Renilla GFP (25) was synthesized (GenScript) and 
cloned into pcDNA3.1. We added the SV40 large T antigen NLS 
PKKKRKVEDPKS (66) by PCR, using an oligonucleotide containing 
the C-terminal 24 bp of rGFP (25), a 9-bp linker (GGTGGATCC), 
and the coding sequence of the NLS: CCGAAGAAAAAAAG-
GAAGGTTGAAGATCCGAAATCG. Nuclear localization of the 
resulting construct was confirmed by colocalization with DAPI. The 
FYVE domain of endofin that localizes to Rab5+ early endosomes 
was fused to the C terminus of rGFP (rGFP-FYVE) (25). Constructs 
were confirmed with DNA sequencing.
Cell culture and transfection
TsA-201 HEK cells were maintained in Dulbecco’s modified Eagle’s 
medium supplemented with 10% FBS (fetal bovine serum), l-glutamine, 
and penicillin/streptomycin at 37°C in 5% CO2. Plasmids were 
transfected using calcium phosphate as previously described (67) or 
Lipofectamine 2000 for the BRET assay (14). The pERK assay was 
done using 1 g of rat TRPV1 plasmid transfected in a 35-mm dish. 
Experiments were performed 24 to 48 hours after transfection. For 
electrophysiology experiments using the -arrestin2 CRISPR cell 
line, gene deletion was achieved by using published CRISPR guide 
RNAs (GAAGTCGAGCCCTAACTGCA and GCGGGACTTCG-
TAGATCACC) (68) cloned into the lentiCRISPR V2 vector 
(Addgene plasmid no. 52961). HEK cells were transfected with 
CRISPR vectors using Lipofectamine LTX (Invitrogen), and cells 
were selected with puromycin (2.5 g/ml). Successful -arrestin2 
knockdown was confirmed by Western blotting analysis.
Western blotting analysis
Two days after transfection, cells were stimulated with RTX, 
harvested, pelleted, and lysed in radioimmunoprecipitation assay 
(RIPA) lysis buffer (1% Igepal, 0.1% SDS, and 0.5% sodium deoxy-
cholate in PBS) supplemented with a protease and phosphatase 
inhibitor cocktail (Complete Mini EDTA-free and PhosStop, 
respectively, Roche). Cleared lysates were separated by SDS–
polyacrylamide gel electrophoresis and transferred to nitrocellulose 
membranes. Membranes were blocked in 5% bovine serum albumin 
(Sigma) or milk in TBS-T [50 mM tris, 150 mM NaCl, and 0.05% 
Tween 20 (pH 7.5)] and probed with the following antibodies: ERK, 
pERK, and -arrestin2 (C16D9) (all at 1:2000; Cell Signaling) and 
glyceraldehyde-3-phosphate dehydrogenase (1:1000; Santa Cruz 
Biotechnology). Horseradish peroxidase–conjugated enhanced 
chemiluminesence–optimized secondary antibodies (GE Healthcare) 
were visualized on a Bio-Rad ChemiDoc. For pERK assays, cells 
were serum-starved for 3 hours before stimulation.
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Quantitative PCR assays
Ipsilateral popliteal lymph nodes were harvested at day 3 and day 8 
after CFA injection, dissociated using a bullet blender (Next 
Advance) with SSB05 beads (Next Advance) in RLT buffer (Qiagen, 
Toronto, Ontario, Canada). Total RNA was extracted using an 
RNeasy Mini kit (Qiagen), according to the manufacturer’s instructions. 
The quality and quantity of RNA were determined using a NanoDrop 
2000c spectrophotometer (Thermo Fisher Scientific, Montréal, 
Quebec, Canada). Relative Proenkephalin (PENK) gene expression 
[normalized to hypoxanthine-guanine phosphoribosyltransferase 
(HPRT)] was determined by quantitative PCR using Quantitect 
SYBR Green PCR Master Mix (Qiagen) and a StepOnePlus real- time 
PCR detection system (Applied Biosystems, Burlington, Ontario, 
Canada). The following primers were used: 5′-GTTCTTTGCT-
GACCTGCTGGAT-3′ and 5′-CCCCGTTGACTGATCATTA-
CAG-3′ for HPRT, 5′-CGACATCAATTTCCTGGCGT-3′ and 
5′-AGATCCTTGCAGGTCTCCCA-3′ for PENK.
Fluorescence-activated cell sorting analysis
At day 8 of CFA, paw tissue was minced and digested in Hanks’ 
balanced salt solution (HBSS) containing collagenase I (1 mg/ml; 
Roche) and dispase (2.4 U/ml; Gibco) for 90 min at 37°C under ag-
itation. After digestion, cells were filtered through a 70-mm mesh 
and washed in PBS 1% FBS. After blocking with CD16/CD32 (1/100 
Fc Block, eBioscience) on ice for 15 min, cells were stained for 
20 min with an anti-mouse CD3–fluorescein isothiocyanate (clone 
145-2C11, BD Biosciences) and anti-mouse CD11b-PercP Cy5.5 
(clone M1/70, eBioscience) and then analyzed on a BD FACSCanto 
II (BD Biosciences).
Immunostaining and confocal microscopy
Cells were plated on MatTek dishes coated overnight with poly- 
ornithine (0.002%), transfected with calcium phosphate, and 
allowed to express for 48 hours before treatment. Cells were then 
fixed in 4% paraformaldehyde. Confocal images were collected on a 
Zeiss LSM-510 Meta inverted microscope using either a 40× water 
immersion or a 63× oil 1.4 numerical aperture oil immersion lens. 
Venus/YFP was visualized by excitation with an argon laser (514 nm), 
and emission was detected using a long-pass 530-nm filter. Enhanced 
GFP was visualized by excitation at 488 nm. Image acquisition was 
performed with identical gain, contrast, laser excitation, pinhole aper-
ture, and laser scanning speed.
Immunostaining of -arrestin2 in DRG neurons was done using 
the monoclonal -arrestin2 (SC-13140, Santa Cruz Biotechnology). 
Alexa Fluor 594 antibody was visualized by excitation with a HeNe 
laser (543 nm), and emission was detected using a 585- to 615-nm 
band-pass filter.
Isolation of DRG neurons
DRG neurons were excised from 6-week-old mice (WT or TRPV1−/−) 
and enzymatically dissociated in HBSS containing collagenase 
(2 mg/ml) and dispase (4 mg/ml; Invitrogen) for 45 min at 37°C (20). 
DRGs were rinsed twice in HBSS and once in culture medium con-
sisting of Dulbecco’s minimum essential medium supplemented 
with 10% heat-inactivated FBS, streptomycin (100 g/ml), penicillin 
(100 U/ml), and nerve growth factor (100 ng/ml; all from Invitrogen). 
Individual neurons were dispersed by trituration through a fire- 
polished glass Pasteur pipette in 4 ml of media. Neurons were cultured 
on glass coverslips previously treated with HBSS + 25% poly-L-ornithine 
and laminin (both from Sigma), overnight at 37°C with 5% CO2 in 
96% humidity.
Quantification of MOR internalization and -arrestin2 
nuclear localization
HEK cells cotransfected with a DNA mix of TRPV1-mCherry and 
MOR-YFP (500 ng each) were treated with vehicle or DAMGO 
(1 M). To assess the effect of TRPV1 activation, cells were pretreat-
ed with capsaicin (100 nM) for 20 min before DAMGO treatment. 
Cells were imaged on a Zeiss LSM-510 Meta inverted confocal mi-
croscope. Images were then analyzed with ImageJ software, using a 
sequence of events including background subtraction and transfor-
mation of MOR-YFP signal to an 8-bit image, adjusting threshold 
and noise reduction. Vesicles within the cells were then counted 
using ImageJ macro. The same sequences of events using identical 
settings were consistently applied to each image.
To quantify the extent of -arrestin2 translocation to the nucleus, 
we transfected HEK cells on coverslips with YFP-arr2 with or 
without TRPV1 and allowed the plasmids to express for 48 hours. 
Cells were then washed in HBSS and stimulated with 1 M capsaicin 
for 15 min at 37°C. The 15-min–time point coverslips were fixed, 
medium was replaced, and then the remaining coverslips were fixed 
at 30, 60, and 120 min from the beginning of stimulation. Covers-
lips were mounted on slides using Prolong Gold Antifade with DAPI 
mountant. Wide-field fluorescent images were acquired on a Zeiss 
LSM-510 Meta confocal microscope, and we quantified the number 
of cells in the field of view that showed YFP-arr2 in the nucleus 
(indicated by DAPI) and the total number of YFP-arr2–positive 
cells.
BRET assay
BRET assay was performed between MOR-Rluc8 and ARR2- 
Venus, MOR-YFP and ARR2-Rluc, or ARR2-RlucII and PAR2-
YFP, as previously described (14, 64). Briefly, HEK cells were 
cotransfected with a DNA mix of 100 ng: 1 g (donor-acceptor) 
(+100 ng of TRPV1, TRPA1, or pCDNA3 as control), using Lipo-
fectamine (Invitrogen). At the next day of transfection, cells were 
plated in a white 96-well plate (BRAND). The agonist-induced BRET 
signal was calculated as the difference in BRET signal from cells 
treated with agonist or vehicle. For the dose-response BRET curve, 
cells were incubated with different concentrations of DAMGO for 
15 min at 37°C and then washed and treated with the RLuc sub-
strate coelenterazine h (5 M) for 5 min before BRET measurement. 
BRET signal was measured in a Mithras LB940 (Berthold Technolo-
gies) and calculated as the ratio of YFP emission (530 nm) to the 
RLuc emission at (460 nm). BRET signal was expressed as net BRET, 
which is the difference between the signal from YFP/RLuc and the 
signal from RLuc alone.
For BRET assay between MOR-YFP and ARR2-Rluc, cells were 
transfected in 96-well plates using Lipofectamine 2000 (Invitrogen) 
with a DNA mix containing 100 ng of MOR-YFP plasmid [provided 
by S. Granier (Institut de Genomique Fonctionelle Montpellier)] and 
2 ng of ARR2-Rluc plasmid [provided by M. G. Scott (Institut 
Cochin, Paris, France)] and 40 ng of TRPV1 plasmid [obtained from 
K. Talavera (Leuven, Belgium)] or empty vector. Twenty-four hours 
after transfection, BRET signal was measured using the pharmaco-
logical screening platform of the IGF, ARPEGE (www.arpege.cnrs.fr). 
Cells were washed twice with PBS and treated with coelanterazine-h 
(5 M) for 5 min before stimulation with DAMGO (10 M) or 
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capsaicin (500 nM) or DAMGO and capsaicin. For bystander BRET, 
cells were transfected with a DNA mix of -arr2-rLuc (100 ng), 
rGFP- NLS (100 ng), and TRPV1 or TRPA1 (100 ng).
Electrophysiology
Whole-cell patch-clamp experiments on HEK cells were performed 
16 to 24 hours after transfection with calcium phosphate (69). The 
internal pipette solution contained the following: 110 mM CsCl, 
3 mM MgCl2, 10 mM EGTA, 10 mM Hepes, 5 mM MgATP, and 
1 mM GTP (pH 7.2 adjusted with CsOH). The bath solution con-
tained the following: 20 mM BaCl2, 1 mM MgCl2, 10 mM Hepes, 
40 mM TEA-Cl, 65 mM CsCl, and 10 mM d-glucose (pH 7.4 adjusted 
with TEA-OH) for HEK cells and 10 mM BaCl2, 10 mM Hepes, 
120 mM TEA-Cl, and 10 mM d-glucose (pH 7.4 adjusted with TEA-
OH) for DRG. The DRG recording solution also contained 10 M 
nifedipine (Sigma, USA) to inhibit L-type calcium currents. The 
recording solutions used for TRPV1 currents contained the 
following: 140 mM NaCl, 1.5 mM CaCl2, 2 mM MgCl2, 5 mM 
KCl, 10 mM Hepes, and 10 mM d-glucose (pH 7.4 adjusted with 
NaOH) and the same internal solution mentioned above. In cells 
that showed TRPV1 currents, the external solution was switched to 
the barium-containing solution mentioned above to record voltage- 
gated calcium currents. Patch-clamp experiments were performed 
using an Axopatch 200B amplifier (Axon Instruments), and pClamp 
10.5 software was used for data acquisition and analysis (both from 
Molecular Devices Corp.). Data were digitized at 10 kHz and low-
pass– filtered at 1 kHz. Borosilicate glass (Harvard Apparatus Ltd.) 
pipettes were pulled and polished to a resistance of 2 to 5 megohms 
with a DMZ-Universal Puller (Zeitz-Instruments GmbH.). When 
applicable, voltages were corrected for liquid junction potentials. All 
experiments were conducted at room temperature (22° ± 2°C).
Immunoprecipitation
For immunoprecipitation, 7.5 g of TRPV1-HA and MOR1-YFP 
complementary DNA (cDNA) were cotransfected into tsA201 cells 
in 10-cm plates at about 50% confluency, using the calcium phos-
phate method. Cells were harvested 48 hours later into 5 ml of PBS 
and treated in suspension with 10 M DAMGO for 15 min at 
37°C. Cells were then centrifuged, and the pellet was lysed in RIPA 
with protease inhibitor (Roche Complete Mini without EDTA) for 
1 hour on ice. TRPV1 was immunoprecipitated from lysates using 
monoclonal anti-HA agarose conjugate (Sigma) overnight at 
4°C. Agarose beads with bound protein were washed three times in 
RIPA; bound proteins were eluted in Laemmli buffer for 30 min at 
37°C and run on a tris-glycine gel. Separated proteins were trans-
ferred to a nitrocellulose membrane and blotted for HA (1:1000; 
Covance) and GFP (1:5000; Torrey Pines).
Statistical analysis
Data analysis was completed with Clampfit 10.5 software (Axon 
Instruments) or GraphPad Prism 7 (GraphPad software). Graphs 
and statistical analyses for electrophysiology experiments were 
performed with Origin 7.0 analysis software (OriginLab). Results 
were expressed as means ± SEM, and SD and numbers in parentheses 
reflect the number of cells (n). Statistical analyses were completed 
with either paired t tests for all the results obtained before and after 
treatment with DAMGO in the same cells or unpaired t tests when 
data were obtained from different cells. Where appropriate, ANOVA 
followed by Bonferroni or Sidak’s post hoc test were performed. 
The criterion for statistical significance was set at P < 0.05 regardless 
of the method used.
SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/12/575/eaav0711/DC1
Fig. S1. The translocation of -arrestin2 to the nucleus is dependent on TRPV1 activation and 
accompanied by a transient PKCII-dependent phosphorylation of ERK1/2.
Fig. S2. Activation of TRPV1 prevents MOR and PAR2 from interacting with -arrestin2.
Fig. S3. The nuclear translocation of -arrestin2 after TRPV1 stimulation is associated with 
impaired MOR internalization.
Fig. S4. DAMGO and capsaicin have no detectable effects on CaV2.2 inhibition in the absence 
of MOR and TRPV1.
Fig. S5. Peripheral endogenous control of inflammatory pain is absent in female TRPV1-
deficient mice.
Fig. S6. Paw edema, T lymphocyte infiltration, and opioid production are not altered in 
TRPV1−/− mice.
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and may identify ways to therapeutically prevent the need for opiate dose escalation.
facilitate its desensitization. This finding potentially explains the analgesic effect of inflammation in patients taking opioids 
-opioid receptor andµ-arrestin2 within the cell such that it could not interact with the βin mice by relocalizing the protein 
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require greater doses. Inflammation, which is common with painful injuries, enhances the analgesic efficacy of opioids. 
Opiates provide pain relief, but they are addictive, and patients often become desensitized to them and then
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